R
Rachel A. Carter
Researcher at Fred Hutchinson Cancer Research Center
Publications - 21
Citations - 5716
Rachel A. Carter is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 15, co-authored 20 publications receiving 5485 citations. Previous affiliations of Rachel A. Carter include University of Washington.
Papers
More filters
Journal ArticleDOI
Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients
Kieren A. Marr,Rachel A. Carter,Fulvio Crippa,Anna Wald,Anna Wald,Lawrence Corey,Lawrence Corey +6 more
TL;DR: The results of the present study demonstrate the changing epidemiology of mould infections, emphasizing the increasing importance of amphotericin B--resistant organisms and the differences in risks and outcome of infection with different filamentous fungi.
Journal ArticleDOI
Measurement characteristics of the Women's Health Initiative food frequency questionnaire.
Ruth E. Patterson,Alan R. Kristal,Lesley F. Tinker,Rachel A. Carter,Mary Pat Bolton,Tanya Agurs-Collins +5 more
TL;DR: Comparison of WHI FFQ nutrient intake measures to independent and unbiased measures, such as doubly labeled water estimates of energy expenditure, are needed to help address the validity of the FFQ in this population.
Journal ArticleDOI
Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors
TL;DR: Risk factor analyses verify previously recognized risk factors (GVHD, receipt of corticosteroids, and neutropenia) and uncover the roles of lymphopenia and viral infections in increasing the incidence of postengraftment IA in the 1990s.
Journal ArticleDOI
Combination Antifungal Therapy for Invasive Aspergillosis
Kieren A. Marr,Kieren A. Marr,Michael Boeckh,Michael Boeckh,Rachel A. Carter,Hyung W. Kim,Lawrence Corey,Lawrence Corey +7 more
TL;DR: In this paper, the authors evaluated the outcomes of patients with aspergillosis who experienced failure of initial therapy with amphotericin B formulations and received either voriconazole (n = 31) or a combination of VORICONZO and Caspofungin(n = 16) for salvage therapy.
Journal ArticleDOI
Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning.
Takahiro Fukuda,Michael Boeckh,Michael Boeckh,Rachel A. Carter,Rachel A. Carter,Brenda M. Sandmaier,Brenda M. Sandmaier,Michael B. Maris,Michael B. Maris,David G. Maloney,David G. Maloney,Paul J. Martin,Paul J. Martin,Rainer Storb,Rainer Storb,Kieren A. Marr +15 more
TL;DR: More effective strategies are needed to prevent invasive mold infections, which currently account for a notable proportion of nonrelapse mortality after nonmyeloablative allogeneic HCT.